Evidence map›Paper›PMID 39446246›Full record

ArticleJournal of physiology and biochemistry2024

TAF15 inhibits p53 nucleus translocation and promotes HCC cell 5-FU resistance via post-transcriptional regulation of UBE2N.

Jiayan Fang, Mengqi Zou, Mei Yang, Yejia Cui, Rong Pu, Yufeng Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of physiology and biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiayan Fang *Department of Internal Medicine-Oncology, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, China.
Mengqi Zou *Department of Pathology, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, No.1, Xianglong Road of Shilong Town, Dongguan, 523326, China.
Mei YangDepartment of Internal Medicine-Oncology, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, China.
Yejia CuiDepartment of Laboratory, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, China.
Rong PuDepartment of Laboratory, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, China.
Yufeng YangDepartment of Pathology, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, No.1, Xianglong Road of Shilong Town, Dongguan, 523326, China. yang_y_f_2024@163.com.

Funding

Dongguan Science and Technology of Social Development Program 20221800906182Dongguan Science and Technology of Social Development Program 20231800935452Incubation Fund of Dongguan Songshan Lake Central Hospital GZR003
6 · The paper itself

Abstract

Chemotherapy resistance is an important factor responsible for the low 5-year survival rate of hepatocellular carcinoma (HCC) patients. Ubiquitin-conjugating enzyme E2N (UBE2N) is a cancer-associated ubiquitin-conjugating enzyme that is expressed in HCC tissues, and its high expression is associated with a poor prognosis. This study explored the role played by UBE2N in development of 5-fluorouracil (5-FU) resistance in HCC cells. Three HCC cell lines (HepG2 [p53 wild type], Huh7 [p53 point mutant type], Hep3B [p53 non-expression type]), and one normal liver cell line (MIHA) were used in our present study. The IC50 value of 5-FU was determined using a cell counting kit-8 (CCK-8) assay. Cell viability was assessed by colony formation assays. TUNEL assays and flow cytometry were used to analyze cell apoptosis. RNA pull-down and RNA immunoprecipitation (RIP) assays were performed to confirm the binding relationship between UBE2N mRNA and TAF15 protein. Our results showed that TAF15 and UBE2N were highly expressed in HCC cells. UBE2N inhibited the translocation of p53 protein into the cell nucleus to increase 5-FU resistance, as reflected by an increased IC50 value, an increase in cell viability, and a reduction in cell apoptosis. Overexpression of p53 reduced 5-FU resistance, but that effect could be reversed by UBE2N overexpression. TAF15 protein bound to and stabilized UBE2N mRNA, thereby inhibiting p53 translocation into the nucleus and promoting 5-FU resistance in HCC cells. Collectively, our present study identified a novel mechanism by which TAF15/UBE2N regulates p53 distribution to increase 5-FU resistance. Our results also suggest potential therapeutic strategies for treating HCC.

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmFluorouracilLiver NeoplasmsTumor Suppressor Protein p53Ubiquitin-Conjugating EnzymesActive Transport, Cell NucleusAntimetabolites, AntineoplasticApoptosisCell Line, TumorCell NucleusGene Expression Regulation, NeoplasticHep G2 CellsHumansTATA-Binding Protein Associated FactorsAntimetabolites, AntineoplasticFluorouracilTATA-Binding Protein Associated FactorsTP53 protein, humanTumor Suppressor Protein p53UBE2N protein, humanUbiquitin-Conjugating Enzymes5-FU resistanceHepatocellular carcinomap53TAF15UBE2N

Identifiers

PMID39446246

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.